Polyphor (SIX: POLN) and EnBiotix Inc., a privately held late clinical-stage rare disease company currently focused on products for rare, chronic respiratory diseases, have signed a merger agreement pursuant to which Polyphor acquires all of the outstanding capital stock of EnBiotix in exchange for shares of Polyphor common stock. EnBiotix also acquires Inhaled Murepavadin at an agreed valuation of USD 10m in exchange for 2'599'655 of common shares of EnBiotix. The completion of merger will create a late stage clinical development company with two clinical programs in cystic fibrosis. VISCHER AG advises Polyphor AG.
The team is led by Matthias Staehelin with Christian Wyss, David Jenny, and Luzius Zumstein (all Corporate/M&A), Marc Prinz (Employment) and Nadia Tarolli (Taxes).